000137560 001__ 137560
000137560 005__ 20240229105110.0
000137560 0247_ $$2doi$$a10.18632/oncotarget.25986
000137560 0247_ $$2pmid$$apmid:30197759
000137560 0247_ $$2pmc$$apmc:PMC6126698
000137560 0247_ $$2altmetric$$aaltmetric:48117969
000137560 037__ $$aDKFZ-2018-01440
000137560 041__ $$aeng
000137560 082__ $$a610
000137560 1001_ $$0P:(DE-He78)70e630b77e8ddc41353fc23197569b7c$$aKordass, Theresa$$b0$$eFirst author$$udkfz
000137560 245__ $$amiR-193b and miR-30c-1* inhibit, whereas miR-576-5p enhances melanoma cell invasion in vitro.
000137560 260__ $$a[S.l.]$$bImpact Journals LLC$$c2018
000137560 3367_ $$2DRIVER$$aarticle
000137560 3367_ $$2DataCite$$aOutput Types/Journal article
000137560 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1537275234_23976
000137560 3367_ $$2BibTeX$$aARTICLE
000137560 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000137560 3367_ $$00$$2EndNote$$aJournal Article
000137560 520__ $$aIn cancer cells, microRNAs (miRNAs) are often aberrantly expressed resulting in impaired mRNA translation. In this study we show that miR-193b and miR-30c-1* inhibit, whereas miR-576-5p accelerates invasion of various human melanoma cell lines. Using Boyden chamber invasion assays the effect of selected miRNAs on the invasive capacity of various human melanoma cell lines was analyzed. Upon gene expression profiling performed on transfected A375 cells, CTGF, THBS1, STMN1, BCL9, RAC1 and MCL1 were identified as potential targets. For target validation, qPCR, Western blot analyses or luciferase reporter assays were applied. This study reveals opposed effects of miR-193b / miR-30c-1* and miR-576-5p, respectively, on melanoma cell invasion and on expression of BCL9 and MCL1, possibly accounting for the contrasting invasive phenotypes observed in A375 cells transfected with these miRNAs. The miRNAs studied and their targets identified fit well into a model proposed by us explaining the regulation of invasion associated genes and the observed opposed phenotypes as a result of networked direct and indirect miRNA / target interactions. The results of this study suggest miR-193b and miR-30c-1* as tumor-suppressive miRNAs, whereas miR-576-5p appears as potential tumor-promoting oncomiR. Thus, miR-193b and miR-30c-1* mimics as well as antagomiRs directed against miR-576-5p might become useful tools in future therapy approaches against advanced melanoma.
000137560 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000137560 588__ $$aDataset connected to CrossRef, PubMed,
000137560 7001_ $$0P:(DE-HGF)0$$aWeber, Claudia E M$$b1
000137560 7001_ $$0P:(DE-He78)3ef7e82c44147a46608c74c80e77ffc9$$aEisel, David$$b2$$udkfz
000137560 7001_ $$0P:(DE-He78)c6c6ce72f4dff102e38d74f7143a2ea8$$aPane, Antonino$$b3$$udkfz
000137560 7001_ $$0P:(DE-He78)b757b21d60bbaa4164899bb7e61b0c15$$aOsen, Wolfram$$b4$$udkfz
000137560 7001_ $$0P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944$$aEichmüller, Stefan$$b5$$eLast author$$udkfz
000137560 773__ $$0PERI:(DE-600)2560162-3$$a10.18632/oncotarget.25986$$gVol. 9, no. 65$$n65$$p32507-32522$$tOncoTarget$$v9$$x1949-2553$$y2018
000137560 909CO $$ooai:inrepo02.dkfz.de:137560$$pVDB
000137560 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)70e630b77e8ddc41353fc23197569b7c$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000137560 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000137560 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3ef7e82c44147a46608c74c80e77ffc9$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000137560 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c6c6ce72f4dff102e38d74f7143a2ea8$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000137560 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b757b21d60bbaa4164899bb7e61b0c15$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000137560 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000137560 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000137560 9141_ $$y2018
000137560 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bONCOTARGET : 2015
000137560 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000137560 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000137560 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000137560 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000137560 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000137560 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000137560 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000137560 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bONCOTARGET : 2015
000137560 9201_ $$0I:(DE-He78)G182-20160331$$kG182$$lGMP Einheit  Zelluläre Therapie$$x0
000137560 980__ $$ajournal
000137560 980__ $$aVDB
000137560 980__ $$aI:(DE-He78)G182-20160331
000137560 980__ $$aUNRESTRICTED